Michael A. Jakupec

Research interests

Publications

• NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

  Chemical Science · 2014 · https://doi.org/10.1039/c3sc53243g

• Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity

  Journal of Medicinal Chemistry · 2009 · https://doi.org/10.1021/jm8013234

• Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation

  Journal of Medicinal Chemistry · 2009 · 10.1021/jm900528d

• Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds

  Organometallics · 2008 · https://doi.org/10.1021/om800207t

• KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

  Chemistry & Biodiversity · 2008 · https://doi.org/10.1002/cbdv.200890195

• Resistance against novel anticancer metal compounds: Differences and similarities

  Drug Resistance Updates · 2008 · https://doi.org/10.1016/j.drup.2008.02.002

• Antitumour metal compounds: more than theme and variations

  Dalton Transactions · 2007 · https://doi.org/10.1039/b712656p

• Structure−Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole): Aquation, Redox Properties, Protein Binding, and Antiproliferative Activity

  Journal of Medicinal Chemistry · 2007 · https://doi.org/10.1021/jm061081y

• Redox behavior of tumor-inhibiting ruthenium( iii ) complexes and effects of physiological reductants on their binding to GMP

  Dalton Transactions · 2006 · https://doi.org/10.1039/b511792e

• From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)

  Journal of Inorganic Biochemistry · 2006 · https://doi.org/10.1016/j.jinorgbio.2006.02.013

• Redox-Active Antineoplastic Ruthenium Complexes with Indazole: Correlation of in Vitro Potency and Reduction Potential

  Journal of Medicinal Chemistry · 2005 · 10.1021/jm0490742

• Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches

  Current Medicinal Chemistry · 2005 · https://doi.org/10.2174/0929867054637626

• Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

  Journal of Analytical Atomic Spectrometry · 2004 · https://doi.org/10.1039/b309160k

• Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells

  Journal of Cancer Research and Clinical Oncology · 2004 · 10.1007/s00432-004-0617-0

• Pharmacological properties of cerium compunds

  Reviews of physiology, biochemistry and pharmacology · 2004 · 10.1007/s10254-004-0024-6

• Tumour-inhibiting platinum complexes—state of the art and future perspectives

  Reviews of physiology, biochemistry and pharmacology · 2003 · 10.1007/s10254-002-0001-x

• Recent Developments in the Field of Tumor-Inhibiting Metal Complexes

  Current Pharmaceutical Design · 2003 · 10.2174/1381612033454180

Current projects

No projects listed.